On November 18th, the PHCN hosted Honourable Terry Lake, BC Minister of Health, and 15 other BC Government MLAs at a MLA’s luncheon in Victoria. Speeches were made about hepatitis C and the policy changes needed to ensure that more people in BC get tested, treated, and cured of hepatitis C.
Daryl Luster, PHCN Board President, described his experience with hepatitis C—beginning to feel ill, 3 years of tests and worsening symptoms, an ‘accidental’ hepatitis C diagnosis, and a fortunate clinical trial where Daryl, after a fairly debilitating round of new and old hep C treatments, cleared the virus. Daryl spoke of how he wanted to spare other hep C patients the experience of worsening symptoms and not being able to find help for far too long. He made a promise then to work hard to see changes that would make it easier for anyone with hepatitis C to get tested, treated, and cured.
Dr. Mel Krajden, Director of BC Hepatitis Services at the BC Centre for Disease Control (BCCDC), presented as well. Dr. Krajden spoke to the different groups of people with hep C—baby boomers, people who use injection drugs, immigrant populations, and aboriginal communities—and about how each group has specific needs. He said that while the Treatment as Prevention is a good approach for reaching and engaging people who are marginalized, other strategies are required. For instance, for baby boomers, he recommends a ‘Test, Triage, and Treat’ approach.
We spoke to the need for new treatments to be listed with PharmaCare with no unnecessary restrictions as soon as possible. We urged the government to seize the opportunity to be leaders in the fight to eradicate hepatitis C—a very real possibility.
Health Minister Lake spoke to the government’s commitment to addressing viral hepatitis and the ongoing negotiations with pharmaceutical companies for new drug prices. The Ministry of Health sees great value in the ‘Treatment as Prevention’ approach.
We hope that the government also sees that different populations have different needs and we want to be smart and strategic in how needs are met!
In addition, Daryl and Dr. Mel Krajden also met with political staff in Minister Lake’s office as well as with Ministry of Health staff in the Population and Public Health branch to discuss these same issues.
Stay tuned for more Hep C TIP Advocacy News!
On December 10th @ 11am PST / 2pm EST, the Canadian Treatment Action Council (CTAC) will be hosting an informative webinar with a survey to follow about the hep C treatment ombitasvir/paritaprevir/ritonavir and dasabuvir. The treatment is currently undergoing a CADTH Common Drug Review (CDR), which is now collecting patient input.
The survey that will follow the Canadian Treatment Action Council webinar is different from PHCN’s patient input survey. Please consider filling out both surveys.
Registration for the webinar is required. Email Adam Cook to register to attend or to get more information about the webinar.
As there seems to be a lot happening around ombitasvir / paritaprevir / ritonavir and dasabuvir (known in Canada as Holkira Pak and Viekira Pak in the USA), with CADTH seeking patient group input reports and PHCN putting out a call for patient input and survey participants, the Hepatitis C Treatment Information Project has put together the following treatment summary:
OMBITASVIR / PARITAPREVIR / RITONAVIR & DASABUVIR (HOLKIRA PAK)
3 DAA Co-formulated Drugs for Genotype 1:
- Ombitasvir / paritaprevir / ritonavir +
- Dasabuvir +/-
- Ribavirin (RBV)
Adult Daily Doses: 4 pills per day +/- ribavirin
- Ombitasvir / paritaprevir / ritonavir: 2 pills in the morning
- Dasabuvir: 1 pill in the morning and 1 pill in the evening
- Ribavirin (RBV): 1 pill in the morning and 1 pill in the evening
Length of Treatment:
12 or 24 weeks
Summary of Phase III Clinical Trial Results:
|Clinical Trial||Patients||Treatment Regimen||SVR12*|
|PEARL-II(12 weeks)||Genotype 1bTreatment-experienced||AbbVie regimen + RBV||97%(85/88)|
|AbbVie regimen only||100%(91/91)|
|PEARL-III(12 weeks)||Genotype 1bTreatment-naive||AbbVie regimen + RBV||99%(209/210)|
|AbbVie regimen only||99%(207/209)|
|PEARL-IV(12 weeks)||Genotype 1aTreatment-naive||AbbVie regimen + RBV||97%(97/100)|
|AbbVie regimen only||90%(185/205)|
|TURQUOISE-II(12 & 24 weeks)||Genotype 1Treatment-naive & treatment-experienced with
|AbbVie regimen + RBV, 12 weeks||92% (191/208)|
|AbbVie regimen + RBV, 24 weeks||96%(165/172)|
|SAPPHIRE-I(12 weeks)||Genotype 1Treatment-naive||AbbVie regimen + RBV||96%(455/473)|
|SAPPHIRE-II(12 weeks)||Genotype 1 treatment-experienced||AbbVie regimen + RBV||96%(286/297)|
*In clinical trials for hepatitis C virus (HCV) infection treatments, the goal is to cure/achieve SVR (sustained viral response)/reduce the virus so that it can’t be detected in the blood and liver disease from hep C is stopped. SVR12 or SVR24 means that the treatments can achieve this response after 12 or 24 weeks of therapy.
During the clinical trials, some reported side effects including headaches, fatigue, itchy skin, nausea, insomnia, and/or diarrhea. Headaches and fatigue were reported similarly by those taking the AbbVie regimen without ribavirin (RBV) and those taking it with ribavirin (RBV).
Please email firstname.lastname@example.org for more information about the survey or visit PHCN’s Hepatitis C Treatment Information Project for more information about ombitasvir / paritaprevir / ritonavir and dasabuvir and the different hep C treatments within the drug approval process.
Take this survey.
Survey participants with hep C or living with/caring for someone with hep C wholesale mlb jerseys needed immediately!
The LEDIPASVIR/SOFOSBUVIR Canadian Agency for Drugs and Technologies in Health (CADTH) is currently seeking patient group input reports for ombitasvir / paritaprevir Copyright / ritonavir and dasabuvir (HOLKIRA PAK), developed by AbbVie. Thus, Pacific Hepatitis C Network (PHCN) needs your help for our report.
The patient group input reports requested by CADTH are an important step towards getting new treatments for hep C more widely available in Canada and BC. You can be a part of this process!
The survey is newly la redesigned and includes 33 questions, mostly multiple choice, that are divided into five sections. cheap jerseys The sections that don’t needed pertain to you, such as the section about your experience with ombitasvir / paritaprevir / ritonavir and dasabuvir (HOLKIRA PAK) if you’ve never taken this hep C treatment, can be easily skipped. Those living with/caring for Managing someone with hep Simeprevir C are only asked to complete eight questions.
Survey responses are anonymous (we wholesale jerseys don’t for know your name or Истребитель other information about you). The information gathered will be used as part of a patient group input report for CADTH. By completing the survey you accept that PHCN can лиц use the information gathered by it in our patient group input report for CADTH.
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.
Please email email@example.com for more information about the survey or visit PHCN’s Hepatitis C Treatment Information Project for more information about ombitasvir / paritaprevir / ritonavir and dasabuvir (HOLKIRA PAK) and the different hep C treatments within the drug pipeline.
Janssen Inc.’s simeprevir, brand name Galexos, in combination with peginterferon/ribavirin was V110 just approved by BC’s PharmaCare for the treatment of chronic hepatitis C genotype 1 in patients with or without Notice compensated cirrhosis and who have:
- never tried to treat their wholesale nfl jerseys hepatitis C
- tried treatment but the virus came back
- tried treatment but weren’t cured
- Lab-confirmed hepatitis C genotype 1
- A prescription for the treatment from a qualified healthcare provider
- Detectable levels of hep C in the last 6 months
- Recent lab-confirmation of NS3 Q80K polymorphism negative for patients with hep C genotype 1a cheap jerseys subtype or genotype 1 with indeterminate subtype. Retesting is required is for all those who had their genotype tested before May 1, 2012.
- A liver fibrosis stage F2 or greater
Please ask your wholesale jerseys healthcare provider for more information about simeprevir (Galexos) in combination with peginterferon/ribavirin (PegIFN/RBV) and about other hep C cheap mlb jerseys treatments.
For more Survey information about currently Bro approved hep C treatments in BC, emerging treatments, the drug approval process in Canada and BC, or hep C support programs, please visit PHCN’s Hepatitis C Treatment Information Project or email firstname.lastname@example.org.
Gilead Sciences, Inc. announced yesterday that Health Canada has issued a Notice of Compliance for ledipasvir/sofosbuvir (Harvoni), the first ?irketleri once-daily single tablet regimen for the treatment of chronic hepatitis C genotype Dr.SiLnT 1 infection in adults. The technical tablet combines wholesale NFL jerseys the NS5A inhibitor ledipasvir with the Wholesale Miami Dolphins Jerseys nucleotide analog polymerase inhibitor sofosbuvir (Sovaldi) cheap NFL jerseys for a 8, 12, or 24 week treatment duration.
The press release programa that Gilead Sciences posted TAKERS! regarding this ledipasvir/sofosbuvir development also includes information about Gilead’s Momentum Support Program in wholesale jerseys Canada.
For more information about currently approved hep C treatments in BC, new and Winter, emerging drugs, ASAP! the drug approval process in Canada and BC, or hep C support programs, please visit PHCN’s Hepatitis C Treatment Information Project or email email@example.com.
Pacific Hepatitis C Network (PHCN) would like to thank all of those who completed our ledipasvir/sofosbuvir (Harvoni) survey.
The survey was completed wholesale jerseys by dünya! more members than pastor expected and the opinions and experiences that were shared were not just invaluable while writing the patient group input report for the Canadian Agency for Drugs and Technologies in Health (CADTH), but will also be invaluable while creating future surveys.
Yes, there will be future surveys and future blog posts similar to the last post, requesting survey takers, and this post, thanking survey takers. Our task is not done! New hep C treatments are currently making their way through the wholesale jerseys China drug pipeline and we have to be a part of this process!
As we use your comments and suggestions to tweak the ledipasvir/sofosbuvir participants (Harvoni) survey for possible future use, we wait in great anticipation for the next time patient input is cheap jerseys requested by CADTH. Please join us in this anticipation and keep a look out for future requests for survey participants as new treatments are coming and CADTH will again need to hear about our experiences with hep C and our opinions about treatments.
For more information about currently approved hep C фундамент treatments in BC, new and emerging drugs, the drug approval process in Canada and BC, or resources to help wholesale mlb jerseys in getting ready for gegen treatment, please visit PHCN’s Hepatitis C Treatment Information Project or email firstname.lastname@example.org.